According to Cognitive Market Research, the global Gastric Cancer Drug market size will be USD 5484.2 million in 2024. It will expand at a compound annual growth rate (CAGR) of 13.00% from 2024 to 2031.
North America held the major market share for more than 40% of the global revenue with a market size of USD 2193.68 million in 2024 and will grow at a compound annual growth rate (CAGR) of 11.2% from 2024 to 2031.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD XX million.
Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 1261.37 million in 2024 and will grow at a compound annual growth rate (CAGR) of 15.0% from 2024 to 2031.
Latin America had a market share of more than 5% of the global revenue with a market size of USD 274.21 million in 2024 and will grow at a compound annual growth rate (CAGR) of 12.4% from 2024 to 2031.
Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 109.68 million in 2024 and will grow at a compound annual growth rate (CAGR) of 12.7% from 2024 to 2031.
The Hospital pharmacies are the dominant distribution channel in the gastric cancer drug market. This dominance stems from the critical role hospital settings play in the administration and management of complex cancer therapies.
